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Investigator led trials, whether of novel pharmaceutical
agents, surgery or complex non-drug therapies, face a
particular set of challenges. This is a selective review,
based on personal observations and experiences of trials
in my own field of stroke and clinical neuroscience over
the past 32 years.
The guiding principles of clinical trials – all too often
lost in the process of designing and managing clinical
trials - are: trials should address a ‘burning question’; to
provide sufficiently reliable evidence to answer that
burning question (i.e. sufficient to change practice),
trials need to be large; to achieve large sample sizes,
trials need to be affordable and efficient in design and
conduct; and, investigators need rigorously to apply the
principles of the ‘business model’ of clinical trials to
help overcome the many obstacles that inhibit trials.
From the 1980’s and into the early 2000’s, a series of
very successful large-scale investigator- led trials in car-
diovascular medicine and neuroscience had a substantial
impact on clinical practice worldwide: the ISIS 1,2,3 & 4
trials in acute myocardial infarction, IST and CAST in
acute stroke, CRASH in traumatic brain injury, ISAT in
the management of ruptured intracranial aneurysms. All
of these trials were conducted on remarkably modest
budgets by today’s standards. After 2004, the regulatory
environment changed significantly – especially for trials
in the UK – with the implementation of the EU direc-
tive on clinical trials, the changes to UK ethical
approvals system, and the introduction of the research
governance framework. These changes have undoubt-
edly substantially raised the costs of, and delayed imple-
mentation of, clinical trials (and I would argue those
costs and delays have disproportionately increased for
investigator-led trials).
There is little disagreement that trials like those listed
above simply could not be undertaken in the current
regulatory environment. Clinical trials in the 21st cen-
tury must therefore adapt to the new environment (or
die). However, for investigators planning their own trials
now, there are grounds for a degree of optimism, since
in the UK at least, several changes are underway that
reduce the risk that investigator trials might become
extinct. To name a few of these changes: the regulatory
environment will ease a little; the number of registered
clinical trials units in the UK has substantially increased
to support new investigators, and the NIHR/MRC fund-
ing models are adapting to meet the needs of clinical
trials; and, other changes are underway internationally
that may also facilitate investigator-led trials.
Published: 13 December 2011
doi:10.1186/1745-6215-12-S1-A94
Cite this article as: Sandercock: Investigator led trials: challenges and
opportunities. Trials 2011 12(Suppl 1):A94.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
University of Edinburgh, Department of Clinical Neurosciences, Western
General Hospital, Edinburgh EH4 2XU, UK
Sandercock Trials 2011, 12(Suppl 1):A94
http://www.trialsjournal.com/content/12/S1/A94 TRIALS
© 2011 Sandercock; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
